Trial Profile
A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2023 Planned End Date changed from 1 Jun 2024 to 1 Mar 2025.
- 04 Dec 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.
- 23 Mar 2023 Status changed from recruiting to active, no longer recruiting.